Back to top
more

Fulcrum Therapeutics (FULC)

(Real Time Quote from BATS)

$3.86 USD

3.86
21,854

-0.01 (-0.26%)

Updated Oct 3, 2024 10:04 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (75 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Reata (RETA) Stock Up Following Q3 Earnings & Sales Beat

by Zacks Equity Research

Reata (RETA) beats estimates for earnings and sales. An advisory committee meeting is scheduled on Dec 8 to discuss bardoxolone NDA.

Axsome (AXSM) Q3 Earnings Top, Pre-Launch Activities Continue

by Zacks Equity Research

Axsome Therapeutics (AXSM) reports a narrower-than-expected Q3 loss. The company is actively preparing to support the commercial launch of its two under-review candidates, AXS-05 and AXS-07.

Fulcrum Therapeutics, Inc. (FULC) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Fulcrum Therapeutics, Inc. (FULC) delivered earnings and revenue surprises of 10.94% and 68.03%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Galera (GRTX) Tanks As Oral Mucositis Study Fails to Meet Goal

by Zacks Equity Research

Galera's (GRTX) phase III ROMAN study on avasopasem for treating radiotherapy-induced severe oral mucositis in patients with head and neck cancer fails to meet its primary endpoint. Shares fall.

    Radius' (RDUS) Study on Tymlos for Osteoporosis in Men Meets Goal

    by Zacks Equity Research

    Radius (RDUS) reports positive top-line results from the ATOM study evaluating Tymlos (abaloparatide) subcutaneous injection for use in men with osteoporosis. The study met the primary endpoint.

    Oyster Point's (OYST) Tyrvaya Gets FDA Nod for Dry Eye Disease

    by Zacks Equity Research

    The FDA approves Oyster Point's (OYST) Tyrvaya nasal spray for the treatment of the signs and symptoms of dry eye disease.

      Can Fulcrum Therapeutics, Inc. (FULC) Climb 31% to Reach the Level Wall Street Analysts Expect?

      by Zacks Equity Research

      The consensus price target hints at a 30.9% upside potential for Fulcrum Therapeutics, Inc. (FULC). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

      Fulcrum Therapeutics, Inc. (FULC) Reports Q2 Loss, Tops Revenue Estimates

      by Zacks Equity Research

      Fulcrum Therapeutics, Inc. (FULC) delivered earnings and revenue surprises of 7.69% and 62.68%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

      Will Fulcrum Therapeutics, Inc. (FULC) Report Negative Q2 Earnings? What You Should Know

      by Zacks Equity Research

      Fulcrum Therapeutics, Inc. (FULC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

      Fulcrum Therapeutics, Inc. (FULC) Reports Q1 Loss, Tops Revenue Estimates

      by Zacks Equity Research

      Fulcrum Therapeutics, Inc. (FULC) delivered earnings and revenue surprises of 18.18% and 119.38%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

      Fulcrum Therapeutics, Inc. (FULC) Reports Q4 Loss, Tops Revenue Estimates

      by Zacks Equity Research

      Fulcrum Therapeutics, Inc. (FULC) delivered earnings and revenue surprises of 12.33% and 153.60%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

      Kodiak Sciences (KOD) Q3 Earnings Miss, KSI-301 in Focus

      by Zacks Equity Research

      Kodiak Sciences (KOD) reports wider-than-expected loss in the third quarter of 2020. The company is progressing well with the development of its lead pipeline candidate KSI-301.

      Novavax (NVAX) Loss Widens in Q3, Revenues Lag Estimates

      by Zacks Equity Research

      Novavax's (NVAX) bottom line deteriorates year over year in the third quarter of 2020. Revenues fall shy of estimates as well. Stock dips in after-hours trading.

      Fulcrum Therapeutics' (FULC) Shares March Higher, Can It Continue?

      by Zacks Equity Research

      As of late, it has definitely been a great time to be an investor in Fulcrum Therapeutics (FULC).

      Puma (PBYI) Down 8% on Q3 Earnings Lag, Nerlynx Sales View Cut

      by Zacks Equity Research

      Puma Biotech (PBYI) falls more than 8% as it misses on both earnings and revenues in the third quarter of 2020. The company trims its 2020 revenue guidance for Nerlynx.

      Why Fulcrum Therapeutics (FULC) Might Surprise This Earnings Season

      by Zacks Equity Research

      Fulcrum Therapeutics (FULC) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

      Axsome's (AXSM) Q3 Earnings In Line, Pipeline Progresses

      by Zacks Equity Research

      Axsome (AXSM) earnings meet estimates in the third quarter. The company stretches the timeline for the NDA filing for AXS-05 and AXS-07. Shares fall.

      Editas' (EDIT) Earnings Rise Y/Y in Q3, EDIT-101 in Focus

      by Zacks Equity Research

      Editas' (EDIT) bottom line grows year over year in the third quarter while revenues beat estimates. Stock rises is after-hours trading.

      Agios' (AGIO) Q3 Loss Wider Than Expected, Revenues Miss

      by Zacks Equity Research

      Agios' (AGIO) earnings and revenues fall shy of estimates in the third quarter. The company lifts the lower end of 2020 sales guidance for its leukemia drug Tibsovo. Stock inches up.

      ACADIA (ACAD) Q3 Earnings Miss, Nuplazid Drives Revenues Y/Y

      by Zacks Equity Research

      ACADIA's (ACAD) earnings fall shy of estimates in the third quarter while revenues beat the same. The company maintains its net sales guidance for Nuplazid. Stock dips in after-hours trading.

      What's in the Cards for CVS Health (CVS) in Q3 Earnings?

      by Zacks Equity Research

      CVS Health's (CVS) Q3 earnings might have been affected by issues like lower prescription and soft front store volume due to decline in provider visits.

      National Vision (EYE) to Report Q3 Earnings: What's in Store?

      by Zacks Equity Research

      National Vision's (EYE) contact lens revenue growth is expected to have remained impressive in Q3 on lesser impact of store closures.

      Blueprint Medicines (BPMC) Q3 Earnings Beat, Revenues Rise Y/Y

      by Zacks Equity Research

      Blueprint Medicines' (BPMC) both bottom and the top line trump estimates in Q3. Ayvakit's sales rise sequentially.

      Why Earnings Season Could Be Great for Fulcrum Therapeutics (FULC)

      by Zacks Equity Research

      Fulcrum Therapeutics (FULC) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

      Bionano (BNGO) to Report Q2 Earnings: What's in the Offing?

      by Zacks Equity Research

      Bionano's (BNGO) sales numbers will be in focus when it reports Q2 results later in the week.